Tandem Diabetes Care Stock Probability of Future Stock Price Finishing Over 49.57
| TNDM Stock | USD 35.91 2.64 7.94% |
Tandem |
Tandem Diabetes Target Price Odds to finish over 49.57
The tendency of Tandem Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 49.57 or more in 90 days |
| 35.91 | 90 days | 49.57 | near 1 |
Based on a normal probability distribution, the odds of Tandem Diabetes to move over $ 49.57 or more in 90 days from now is near 1 (This Tandem Diabetes Care probability density function shows the probability of Tandem Stock to fall within a particular range of prices over 90 days) . Probability of Tandem Diabetes Care price to stay between its current price of $ 35.91 and $ 49.57 at the end of the 90-day period is about 40.9 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.05 . This usually implies Tandem Diabetes Care market returns are highly reactive to returns on the market. As the market goes up or down, Tandem Diabetes is expected to follow. Additionally Tandem Diabetes Care has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Tandem Diabetes Price Density |
| Price |
Predictive Modules for Tandem Diabetes
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tandem Diabetes Care. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tandem Diabetes' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Tandem Diabetes Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tandem Diabetes is not an exception. The market had few large corrections towards the Tandem Diabetes' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tandem Diabetes Care, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tandem Diabetes within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.29 | |
β | Beta against Dow Jones | 1.05 | |
σ | Overall volatility | 4.84 | |
Ir | Information ratio | -0.08 |
Tandem Diabetes Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tandem Diabetes for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tandem Diabetes Care can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tandem Diabetes Care generated a negative expected return over the last 90 days | |
| Tandem Diabetes Care has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 412.99 M. | |
| Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47. | |
| Tandem Diabetes Care has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: DexCom, Insulet, Tandem benefit from Novo Nordisk CagriSema data |
Tandem Diabetes Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tandem Stock often depends not only on the future outlook of the current and potential Tandem Diabetes' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tandem Diabetes' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 65 M | |
| Cash And Short Term Investments | 467.9 M |
Tandem Diabetes Technical Analysis
Tandem Diabetes' future price can be derived by breaking down and analyzing its technical indicators over time. Tandem Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Tandem Diabetes Care. In general, you should focus on analyzing Tandem Stock price patterns and their correlations with different microeconomic environments and drivers.
Tandem Diabetes Predictive Forecast Models
Tandem Diabetes' time-series forecasting models is one of many Tandem Diabetes' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Tandem Diabetes' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Tandem Diabetes Care
Checking the ongoing alerts about Tandem Diabetes for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Tandem Diabetes Care help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Tandem Diabetes Care generated a negative expected return over the last 90 days | |
| Tandem Diabetes Care has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 412.99 M. | |
| Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47. | |
| Tandem Diabetes Care has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: DexCom, Insulet, Tandem benefit from Novo Nordisk CagriSema data |
Check out Tandem Diabetes Backtesting, Tandem Diabetes Valuation, Tandem Diabetes Correlation, Tandem Diabetes Hype Analysis, Tandem Diabetes Volatility, Tandem Diabetes History as well as Tandem Diabetes Performance. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.